Clinical Applications of Metabolomics: Advancing Insights into BacterialInfections

Metabolomics, the comprehensive analysis of small-molecule metabolites within
biological systems, has emerged as a powerful analytical platform for advancing the
diagnosis, prognosis, and management of infectious diseases. Leveraging high-
throughput technologies such as mass spectrometry (MS) and nuclear magnetic
resonance (NMR), metabolomics enables the identification of distinct metabolic
fingerprints associated with infections, offering novel metabolomic insights host-
pathogen interactions and disease pathophysiology. MS-based platforms, coupled with
chromatographic techniques like gas chromatography (GC-MS) and liquid
chromatography (LC-MS), provide exceptional sensitivity and specificity for metabolite
detection in biofluids such as blood, urine, and cerebrospinal fluid (CSF). NMR
spectroscopy complements these approaches by enabling non-destructive, reproducible
analyses ideal for longitudinal studies and treatment monitoring. In infectious disease
diagnostics, metabolomics has demonstrated the ability to differentiate bacterial, viral,
and fungal infections through unique metabolic signatures. For example, bacterial sepsis
is characterized by significant perturbations in lipid metabolism, including alterations in
phospholipids and sphingolipids, which correlate with systemic inflammation and
immune activation. Beyond diagnostics, metabolomics contributes to understanding
antimicrobial resistance (AMR) by profiling metabolic reprogramming in resistant
strains, revealing mechanisms such as increased efflux pump activity, biofilm formation,
and membrane remodeling. These insights present potential therapeutic targets and
inform personalized treatment strategies. The integration of metabolomics with genomics
and proteomics further enhances diagnostic and prognostic accuracy. This review details
metabolomics applications in sepsis, meningitis, tuberculosis (TB), respiratory tract
infections (RTIs), UTIs, and Helicobacter pylori (H. pylori) infections, emphasizing its
potential to revolutionize infection management while discussing current challenges and
future directions.